Industry News

• Marker Therapeutics announces headquarters relocation from Jacksonville, FL to Houston, TX  Marker Therapeutics announced it has formally relocated its headquarters from Jacksonville, Florida to Houston, Texas. The Company also announcedit is now a resident company at Johnson & Johnson Innovation – JLABS, an incubator located in the heart of the Texas Medical Center.
  February 15, 2019  
• Researchers find genetic vulnerability to menthol cigarette use  A genetic variant found only in people of African descent increases a smoker’s preference for cigarettes containing menthol, a flavor additive. The variant of the MRGPRX4 gene is five to eight times more frequent among smokers who use menthol cigarettes than other smokers.
  February 15, 2019  
• Hypnosis through virtual reality aids in medical recovery  Anesthesiologists at Southwestern Medical Center are exploring the use of hypnosis through virtual reality to lessen postoperative pain and anxiety in children. The pilot study involved 21 young patients and found that virtual reality hypnosis reduced anxiety, and postoperative opioid consumption.
  February 15, 2019  
• U.S. and EU Patent Office decisions invalidate Amgen subsidiary Immunex's patents  Regeneron announced the EPO revoked Immunex's European Patent No. 2,990,420 in its entirety because the claims were invalid for insufficiency of disclosure. This follows a decision the USPTO to invalidate all 17 claims of Immunex's U.S. Patent No. 8,679,487 as obvious.
  February 15, 2019  
• McDonnell Genome Institute mission expands  The McDonnell Genome Institute at Washington University School of Medicine in St. Louis is entering a new era of genomic medicine, expanding its capacities beyond genome sequencing and adding a new and vital focus on understanding how genetics influences health and disease.
  February 15, 2019  
• Nevro files lawsuit for patent infringement against Stimwave in the U.S.  Nevro announced it has filed a patent infringement lawsuit against Stimwave Technologies. The lawsuit, filed in U.S. District Court for the District of Delaware on Feb. 14, 2019, asserts Stimwave is infringing Nevro's patents covering inventions relating to Nevro's Senza® system and HF10® therapy.
  February 15, 2019  
• CymaBay Therapeutics announces seladelpar granted Breakthrough Therapy Designation by FDA  CymaBay Therapeutics announced the FDA has granted Breakthrough Therapy Designation for seladelpar for treatment of early stage primary biliary cholangitis in combination with ursodeoxycholic acid in adult patients with an inadequate response to UDCA.
  February 15, 2019  
• Pentair announces equity investment in Aqua Membranes  Pentair announced it has closed a minority investment in Aqua Membranes. The patented 3D printed spacer technology of Aqua Membranes enables performance improvement in spiral wound elements used in reverse osmosis membrane applications, including residential and commercial water filtration.
  February 15, 2019  
• FDA grants priority review to Merck’s sBLA for KEYTRUDA® (pembrolizumab) with Inlyta®  Merck announced the FDA has accepted and granted priority review for a new sBLA for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with Inlyta (axitinib), a tyrosine kinase inhibitor, for the first-line treatment of patients with advanced renal cell carcinoma.
  February 15, 2019  
• Achaogen announces pricing of $15 million underwritten public offering  Achaogen announced pricing of an underwritten public offering of 15,000,000 shares of its common stock and accompanying short-term warrants to purchase up to 15,000,000 shares of its common stock and long-term warrants to purchase up to 15,000,000 shares of its common stock.
  February 15, 2019  

   (next 10 articles)